메뉴 건너뛰기




Volumn 23, Issue 3, 2010, Pages 122-125

Antifungal activity of posaconazole against Candida spp. and non-Candida clinical yeasts isolates

Author keywords

Antifungal agent; Candida; Cryptococcus; Posaconazole; Rhodotorula; Susceptibility; Yeasts

Indexed keywords

AMPICILLIN; POSACONAZOLE;

EID: 78651366442     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (9)

References (28)
  • 2
    • 60549085066 scopus 로고    scopus 로고
    • Posaconazole: A new oral antifungal agent with an expanded spectrum of activity
    • Morris MI. Posaconazole: a new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm 2009;66:225-36.
    • (2009) Am J Health Syst Pharm , vol.66 , pp. 225-236
    • Morris, M.I.1
  • 4
    • 3843087937 scopus 로고    scopus 로고
    • Clinical and Laboratory Standards Institute, Wayne Pa.Clinical and Laboratory Standards Institute. Approved Guideline-Second Edition, CLSI document M44-A2. Clinical and Laboratory Standards Institute, Wayne, Pa
    • Clinical and Laboratory Standards Institute, Wayne, Pa.Clinical and Laboratory Standards Institute. 2009. Method for antifungal disk diffusion susceptibility testing of yeasts; Approved Guideline-Second Edition, CLSI document M44-A2. Clinical and Laboratory Standards Institute, Wayne, Pa.
    • (2009) Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts
  • 6
    • 0002621945 scopus 로고    scopus 로고
    • Should resistance to azole antifungals in vitro be interpreted as predicting clinical non-response?
    • Odds FC. Should resistance to azole antifungals in vitro be interpreted as predicting clinical non-response? Drug resistance Updates 1998;1:11-15.
    • (1998) Drug Resistance Updates , vol.1 , pp. 11-15
    • Odds, F.C.1
  • 10
    • 0033916324 scopus 로고    scopus 로고
    • In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Asper-gillus and Candida
    • Cacciapuoti A, Loebenberg D, Corcoran E, Menzel F Jr, Moss EL Jr, Norris C, et al. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Asper-gillus and Candida. Antimicrob Agents Chemother 2000;44:2017-22
    • (2000) Antimicrob Agents Chemother , vol.44 , pp. 2017-2022
    • Cacciapuoti, A.1    Loebenberg, D.2    Corcoran, E.3    Menzel Jr., F.4    Moss Jr., E.L.5    Norris, C.6
  • 11
    • 37548998574 scopus 로고    scopus 로고
    • Comparison of disc diffusion assay with the CLSI reference method (M27-A2) for testing in vitro posaconazole activity against common and uncommon yeasts
    • Cantón E, Pemán J, Espinel-Ingroff A, Martín- Mazuelos E, Carrillo-Muñoz A, Martínez JP. Comparison of disc diffusion assay with the CLSI reference method (M27-A2) for testing in vitro posaconazole activity against common and uncommon yeasts. J Antimicrob Chemother 2008;61:135-8.
    • (2008) J Antimicrob Chemother , vol.61 , pp. 135-138
    • Cantón, E.1    Pemán, J.2    Espinel-Ingroff, A.3    Martín- Mazuelos, E.4    Carrillo-Muñoz, A.5    Martínez, J.P.6
  • 13
    • 0031027261 scopus 로고    scopus 로고
    • In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts
    • Galgiani JN, Lewis ML. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother 1997;41:180-3.
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 180-183
    • Galgiani, J.N.1    Lewis, M.L.2
  • 14
    • 0030821205 scopus 로고    scopus 로고
    • Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp
    • Law D, Moore CB, Denning DW. Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother 1997;41:2310-1.
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 2310-2311
    • Law, D.1    Moore, C.B.2    Denning, D.W.3
  • 16
    • 0029817614 scopus 로고    scopus 로고
    • In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
    • Perfect JR, Cox GM, Dodge RK, Schell WA. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996;40:1910-3.
    • (1996) Antimicrob Agents Chemother , vol.40 , pp. 1910-1913
    • Perfect, J.R.1    Cox, G.M.2    Dodge, R.K.3    Schell, W.A.4
  • 17
    • 0036200361 scopus 로고    scopus 로고
    • Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000
    • Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 2002;40:852-6.
    • (2002) J Clin Microbiol , vol.40 , pp. 852-856
    • Pfaller, M.A.1    Diekema, D.J.2    Jones, R.N.3    Messer, S.A.4    Hollis, R.J.5
  • 18
    • 12244253033 scopus 로고    scopus 로고
    • In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood
    • Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol 2003;41:78-83.
    • (2003) J Clin Microbiol , vol.41 , pp. 78-83
    • Pfaller, M.A.1    Diekema, D.J.2    Messer, S.A.3    Boyken, L.4    Hollis, R.J.5    Jones, R.N.6
  • 19
    • 0034806952 scopus 로고    scopus 로고
    • In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans
    • Pfaller MA, Messer SA, Hollis RJ, Jones RN. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001;45:2862-4.
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 2862-4
    • Pfaller, M.A.1    Messer, S.A.2    Hollis, R.J.3    Jones, R.N.4
  • 20
    • 1542509561 scopus 로고    scopus 로고
    • In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program
    • Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. And Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004;48:201-5.
    • (2004) Diagn Microbiol Infect Dis , vol.48 , pp. 201-205
    • Pfaller, M.A.1    Messer, S.A.2    Boyken, L.3    Hollis, R.J.4    Rice, C.5    Tendolkar, S.6
  • 21
    • 0031760635 scopus 로고    scopus 로고
    • In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole
    • Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, et al. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother 1998;42:3242-4.
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 3242-3244
    • Pfaller, M.A.1    Messer, S.A.2    Hollis, R.J.3    Jones, R.N.4    Doern, G.V.5    Brandt, M.E.6
  • 23
    • 0031052377 scopus 로고    scopus 로고
    • Development of interpretative breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections
    • Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, et al. Development of interpretative breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997;24:248-9.
    • (1997) Clin Infect Dis , vol.24 , pp. 248-9
    • Rex, J.H.1    Pfaller, M.A.2    Galgiani, J.N.3    Bartlett, M.S.4    Espinel-Ingroff, A.5    Ghannoum, M.A.6
  • 24
    • 0034015295 scopus 로고    scopus 로고
    • In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole
    • Yildiran ST, Saracli MA, Fothergill AW, Rinaldi MG. In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole. Eur J Clin Microbiol Infect Dis 2000;19:317-9
    • (2000) Eur J Clin Microbiol Infect Dis , vol.19 , pp. 317-319
    • Yildiran, S.T.1    Saracli, M.A.2    Fothergill, A.W.3    Rinaldi, M.G.4
  • 25
    • 78651351140 scopus 로고    scopus 로고
    • Perfil de actividad antifúngica in vitro de posaconazol. método de difusión en agar (Neosensitabs) basado en el documento M44-A frente a levaduras
    • Carrillo-Muñoz AJ, Hernández-Molina JM, Cárdenes D, Giusiano G, Santos P, Eraso E, et al. Perfil de actividad antifúngica in vitro de posaconazol. método de difusión en agar (Neosensitabs) basado en el documento M44-A frente a levaduras. Rev Iberoam Micol 2008;25:S36.
    • (2008) Rev Iberoam Micol , vol.25
    • Carrillo-Muñoz, A.J.1    Hernández-Molina, J.M.2    Cárdenes, D.3    Giusiano, G.4    Santos, P.5    Eraso, E.6
  • 26
    • 15844411100 scopus 로고    scopus 로고
    • In vitro antifungal activity of posaconazole compared with fluconazole and amphotericin B against clinical yeasts from oropharyngeal candidiasis and other infections
    • Carrillo-Muñoz AJ, Quindós G, Ruesga M, Alonso R, del Valle O, Hernández-Molina JM, et al. In vitro antifungal activity of posaconazole compared with fluconazole and amphotericin B against clinical yeasts from oropharyngeal candidiasis and other infections. J Antimicrob Chemother 2005;55:317-9.
    • (2005) J Antimicrob Chemother , vol.55 , pp. 317-319
    • Carrillo-Muñoz, A.J.1    Quindós, G.2    Ruesga, M.3    Alonso, R.4    Del Valle, O.5    Hernández-Molina, J.M.6
  • 27
    • 4243695651 scopus 로고
    • Pruebas de studio de sensibilidad a los antifúngicos I. Factores y variables que influyen en su realización en el laboratorio
    • Carrillo-Muñoz AJ, Abarca-Salat L, Quindós G. Pruebas de studio de sensibilidad a los antifúngicos I. Factores y variables que influyen en su realización en el laboratorio. Rev Iberoam Micol 1994;11:105-10.
    • (1994) Rev Iberoam Micol , vol.11 , pp. 105-110
    • Carrillo-Muñoz, A.J.1    Abarca-Salat, L.2    Quindós, G.3
  • 28
    • 33750896801 scopus 로고    scopus 로고
    • Evaluación y utilidad de los métodos E-test® y Neo-Sensitabs® para estudiar la sensibilidad de las levaduras al fluconazol
    • Cantón E, Pemán J, Sastre M, Valentín A, Bosch M, Espinel-Ingroff A. Evaluación y utilidad de los métodos E-test® y Neo-Sensitabs® para estudiar la sensibilidad de las levaduras al fluconazol. Rev Esp Quimioter 2006;19:267-74.
    • (2006) Rev Esp Quimioter , vol.19 , pp. 267-274
    • Cantón, E.1    Pemán, J.2    Sastre, M.3    Valentín, A.4    Bosch, M.5    Espinel-Ingroff, A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.